Nanocarrier-Based Drug Delivery for Melanoma Therapeutics.

Abstract

Melanoma, as a tumor cell derived from melanocyte transformation, has the characteristics of malignant proliferation, high metastasis, rapid recurrence, and a low survival rate. Traditional therapy has many shortcomings, including drug side effects and poor patient compliance, and so on. Therefore, the development of an effective treatment is necessary. Currently, nanotechnologies are a promising oncology treatment strategy because of their ability to effectively deliver drugs and other bioactive molecules to targeted tissues with low toxicity, thereby improving the clinical efficacy of cancer therapy. In this review, the application of nanotechnology in the treatment of melanoma is reviewed and discussed. First, the pathogenesis and molecular targets of melanoma are elucidated, and the current clinical treatment strategies and deficiencies of melanoma are then introduced. Following this, we discuss the main features of developing efficient nanosystems and introduce the latest reports in the literature on nanoparticles for the treatment of melanoma. Subsequently, we review and discuss the application of nanoparticles in chemotherapeutic agents, immunotherapy, mRNA vaccines, and photothermal therapy, as well as the potential of nanotechnology in the early diagnosis of melanoma.

• Authors: Mingming Song, Chang Liu, Siyu Chen, Wenxiang Zhang
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 22 Issue 4 (Feb 13 2021) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 33668591 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Drug Carriers

Topics

• Antineoplastic Agents (chemistry, therapeutic use)
• Drug Carriers (chemistry, therapeutic use)
• Humans
• Melanoma (drug therapy, metabolism, pathology)
• Nanoparticles (chemistry, therapeutic use)